
Opinion|Videos|February 27, 2025
BCG for treatment of NMIBC
Experts discuss the use of bacille Calmette-Guérin (BCG) as the standard treatment for high-risk non–muscle-invasive bladder cancer (NMIBC), when a patient is considered unresponsive to BCG, and how BCG shortages have impacted clinical practice and urologists in the community.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- BCG has long been the standard treatment for high-risk NMIBC.
- When do you consider a patient to be unresponsive to BCG?
- How have BCG shortages impacted your practice/urologists in the community
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: December 2025
2
TRT myths, metabolic risk, and the role of the urologist
3
How sex influences the bladder cancer tumor microenvironment
4
John Michael DiBianco, MD, highlights trial of stent omission after ureteroscopy
5



















